Pegylated interferons: chemical and clinical differences

被引：85

作者：

Foster, GR ^{[1
]}

机构：

[1] Barts & Royal London Hosp, Queen Marys Sch Med & Dent, Inst Mol & Cellular Sci, Hepatobiliary Grp, London, England

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2004年 / 20卷 / 08期

关键词：

D O I：

10.1111/j.1365-2036.2004.02170.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Pegylated interferon therapy for the treatment of chronic hepatitis C virus provides significant increases in sustained virological response rates compared with standard interferons. Two pegylated interferons are now available and are used in conjunction with ribavirin to maximize response rates in infected patients. The two pegylated interferons, peginterferonalpha-2a and peginterferonalpha-2b, differ substantially in terms of their chemical and structural characteristics, pharmacokinetic and pharmacodynamic properties, and dosing and administration. A full understanding of the differences between the two drugs is important to maximize the clinical benefits. Controlled studies designed to characterize the effects of the two drugs on viral kinetics and sustained virological response rates are emerging and may help to shed additional light on the use of these compounds in patients with chronic hepatitis C.

引用

收藏

页码：825 / 830

页数：6

相关论文

共 33 条

[1] Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].

Bailon, P ;

Palleroni, A ;

Schaffer, CA ;

Spence, CL ;

Fung, WJ ;

Porter, JE ;

Ehrlich, GK ;

Pan, W ;

Xu, ZX ;

Modi, MW ;

Farid, A ;

Berthold, W .

BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202

[2]

*FDA, 2001, ANT DRUGS ADV COMM P

[3]

*FDA, 2002, ANT DRUGS ADV COMM P

[4]

FLAMM SL, 2003, GASTROENTEROLOGY S1, V124, pA212

[5] Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1 [J].

Formann, E ;

Jessner, W ;

Bennett, L ;

Ferenci, P .

JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) :271-276

[6] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[7] Pegylated interferon-α2b:: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [J].

Glue, P ;

Fang, JWS ;

Rouzier-Panis, R ;

Raffanel, C ;

Sabo, R ;

Gupta, SK ;

Salfi, M ;

Jacobs, S .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :556-567

[8] Structural and biologic characterization of pegylated recombinant IFN-α2b [J].

Grace, M ;

Youngster, S ;

Gitlin, G ;

Sydor, W ;

Xie, L ;

Westreich, L ;

Jacobs, S ;

Brassard, D ;

Bausch, J ;

Bordens, R .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1103-1115

[9] Single-dose pharmacokinetics and safety of pegylated interferon-α2b in patients with chronic renal dysfunction [J].

Gupta, SK ;

Pittenger, AL ;

Swan, SK ;

Marbury, TC ;

Tobillo, E ;

Batra, V ;

Sack, M ;

Glue, P ;

Jacobs, S ;

Affrime, M .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (10) :1109-1115

[10] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

← 1 2 3 4 →